Healthcare Industry News: NSCLC
News Release - August 26, 2011
Abbott Receives FDA Approval for ALK Gene Test for Lung Cancer Therapy SelectionSimultaneous Approval of New Treatment and Companion Diagnostic Represents Significant Advance in Personalized Medicine for Patients with Non-Small-Cell Lung Cancer
ABBOTT PARK, Ill., Aug. 26, 2011 -- (Healthcare Sales & Marketing Network) -- Abbott (NYSE:ABT ) today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC). The new Abbott Vysis ALK Break Apart FISH Probe test is designed to identify ALK-positive NSCLC patients for Pfizer's approved NSCLC therapy, XALKORI® (crizotinib), an oral first-in-class ALK inhibitor.
The Vysis ALK FISH test uses Abbott's fluorescence in situ hybridization (FISH) technology to detect rearrangements of the ALK gene on the 2p23 chromosome. The diagnostic test offers clinicians a standardized, clinically validated method to identify patients more likely to benefit from the new therapy.
"The Abbott-Pfizer collaboration marks a breakthrough in the advancement of personalized medicine – and companion diagnostics specifically – that will help a subset of lung-cancer patients get treatment tailored to their unique genetic profile," said Stafford O'Kelly, head of Abbott's molecular diagnostics business.
The simultaneous FDA approvals are expected to change clinical practice for the diagnosis and treatment of patients with NSCLC. The Abbott ALK test has been designed to identify those patients – about 3 to 5 percent of NSCLC patients – who would be candidates for the new drug.
"The FDA's priority and expedited review process of the drug and combination diagnostic test have been impressive," O'Kelly said. "We expect that many patients newly diagnosed with NSCLC will want to ask their doctors about the potential benefits of this new genetic test."
Lung malignancies are the leading cause of cancer deaths worldwide, with more than 1.6 million new cases diagnosed each year. About 85 percent of lung cancer patients have the non-small-cell type and are usually diagnosed with advanced disease having a very low survival rate.
Abbott's Vysis ALK FISH test will be available to clinicians and pathologists through Abbott Molecular. For more information visit www.AbbottALK.com.
FISH (fluorescence in-situ hybridization) technology has a variety of uses.
It can identify whether too many, or too few, copies of a particular gene are present in the body's cells or whether certain genes have rearrangements that play an active role in disease progression. Since the technology works especially well for identifying genetic markers in solid tumors, cancer diagnostics are one of the fastest growing applications.
Similar to the Abbott ALK test's ability to identify patients for XALKORI® therapy, Abbott's PathVysion test, the first FDA approved FISH-based companion diagnostic, detects amplification of the HER-2 gene and acts as an aid in identifying patients for Herceptin® (trastuzumab) therapy for breast cancer. The Abbott UroVysion test also utilizes FISH technology to quantitatively assess chromosomal changes in the cell's nucleus, which may aid in the diagnosis as well as in the surveillance and monitoring of bladder cancer.
About Abbott Molecular
Abbott Molecular, abbottmolecular.com, is a leader in molecular diagnostics — the analysis of DNA and RNA at the molecular level. Abbott Molecular's tests can also detect subtle but key changes in patients' genes and chromosomes and have the potential for earlier detection or diagnosis, can influence the selection of appropriate therapies, and may improve monitoring of disease progression.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at www.abbott.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAbbott's FreeStyle Libre 2 Now Approved for Adults and Children with Diabetes in Canada, Featuring Unsurpassed 14-Day Accuracy and Optional Alarms
Abbott's FreeStyle(R) Libre 2 iCGM System Now Available to Medicare Beneficiaries
Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation